Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
QQQ   282.71 (-1.47%)
AAPL   144.35 (-2.54%)
MSFT   241.78 (-2.31%)
META   108.74 (-2.40%)
GOOGL   96.00 (-1.50%)
AMZN   93.92 (+0.55%)
TSLA   182.61 (-0.14%)
NVDA   158.50 (-2.58%)
NIO   10.11 (-0.59%)
BABA   75.84 (+0.45%)
AMD   73.19 (-2.60%)
T   18.84 (-1.46%)
MU   55.74 (-4.57%)
CGC   3.41 (-6.83%)
F   13.75 (-2.34%)
GE   85.49 (-3.01%)
DIS   95.70 (-3.21%)
AMC   7.36 (-2.00%)
PYPL   79.92 (-0.20%)
PFE   49.60 (+0.79%)
NFLX   281.33 (-1.47%)
QQQ   282.71 (-1.47%)
AAPL   144.35 (-2.54%)
MSFT   241.78 (-2.31%)
META   108.74 (-2.40%)
GOOGL   96.00 (-1.50%)
AMZN   93.92 (+0.55%)
TSLA   182.61 (-0.14%)
NVDA   158.50 (-2.58%)
NIO   10.11 (-0.59%)
BABA   75.84 (+0.45%)
AMD   73.19 (-2.60%)
T   18.84 (-1.46%)
MU   55.74 (-4.57%)
CGC   3.41 (-6.83%)
F   13.75 (-2.34%)
GE   85.49 (-3.01%)
DIS   95.70 (-3.21%)
AMC   7.36 (-2.00%)
PYPL   79.92 (-0.20%)
PFE   49.60 (+0.79%)
NFLX   281.33 (-1.47%)
QQQ   282.71 (-1.47%)
AAPL   144.35 (-2.54%)
MSFT   241.78 (-2.31%)
META   108.74 (-2.40%)
GOOGL   96.00 (-1.50%)
AMZN   93.92 (+0.55%)
TSLA   182.61 (-0.14%)
NVDA   158.50 (-2.58%)
NIO   10.11 (-0.59%)
BABA   75.84 (+0.45%)
AMD   73.19 (-2.60%)
T   18.84 (-1.46%)
MU   55.74 (-4.57%)
CGC   3.41 (-6.83%)
F   13.75 (-2.34%)
GE   85.49 (-3.01%)
DIS   95.70 (-3.21%)
AMC   7.36 (-2.00%)
PYPL   79.92 (-0.20%)
PFE   49.60 (+0.79%)
NFLX   281.33 (-1.47%)
QQQ   282.71 (-1.47%)
AAPL   144.35 (-2.54%)
MSFT   241.78 (-2.31%)
META   108.74 (-2.40%)
GOOGL   96.00 (-1.50%)
AMZN   93.92 (+0.55%)
TSLA   182.61 (-0.14%)
NVDA   158.50 (-2.58%)
NIO   10.11 (-0.59%)
BABA   75.84 (+0.45%)
AMD   73.19 (-2.60%)
T   18.84 (-1.46%)
MU   55.74 (-4.57%)
CGC   3.41 (-6.83%)
F   13.75 (-2.34%)
GE   85.49 (-3.01%)
DIS   95.70 (-3.21%)
AMC   7.36 (-2.00%)
PYPL   79.92 (-0.20%)
PFE   49.60 (+0.79%)
NFLX   281.33 (-1.47%)
NASDAQ:ICPT

Intercept Pharmaceuticals - ICPT Price Target & Analyst Ratings

$14.55
-0.22 (-1.49%)
(As of 11/28/2022 03:59 PM ET)
Add
Compare
Today's Range
$14.35
$14.84
50-Day Range
$12.91
$17.86
52-Week Range
$10.81
$21.25
Volume
15,180 shs
Average Volume
914,582 shs
Market Capitalization
$602.62 million
P/E Ratio
2.53
Dividend Yield
N/A
Price Target
$25.80

Intercept Pharmaceuticals Consensus Rating and Price Target (2022)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 8 Analyst Ratings

Consensus Analyst Price Target

$25.80
77.32% Upside
High Prediction$49.00
Average Prediction$25.80
Low Prediction$14.00
TypeCurrent
11/28/21 to 11/28/22
1 Month Ago
10/29/21 to 10/29/22
3 Months Ago
8/30/21 to 8/30/22
1 Year Ago
11/28/20 to 11/28/21
Consensus Rating
Moderate Buy
Hold
Hold
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
4 Buy rating(s)
4 Buy rating(s)
3 Buy rating(s)
5 Buy rating(s)
Hold
4 Hold rating(s)
6 Hold rating(s)
6 Hold rating(s)
9 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
2 Sell rating(s)
Consensus Price Target$25.80$25.08$22.10$29.67
Predicted Upside77.32% Upside59.37% Upside36.85% Upside56.27% Upside
Get Intercept Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ICPT and its competitors with MarketBeat's FREE daily newsletter.


ICPT Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ICPT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Intercept Pharmaceuticals Stock vs. The Competition

TypeIntercept PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
2.50
2.66
2.48
Consensus RatingModerate BuyBuyHold
Predicted Upside77.20% Upside756.56% Upside13.64% Upside
News Sentiment RatingPositive News
Positive News
Neutral News
MarketBeat
Community Rating
Outperform Votes
1056
74.79%
Underperform Votes
356
25.21%
Avg. Outperform Votes
163
66.26%
Avg. Underperform Votes
83
33.74%
Avg. Outperform Votes
851
68.13%
Avg. Underperform Votes
398
31.87%

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/16/2022HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral$16.00 ➝ $14.00-9.21%
10/3/2022Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$52.00 ➝ $35.00+150.90%
10/3/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetMarket Perform$21.00 ➝ $17.00+21.86%
9/30/2022Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$82.00 ➝ $49.00+251.25%
8/22/2022B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$30.00 ➝ $28.00+55.99%
8/9/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$22.00+36.48%
8/4/2022Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$23.00 ➝ $26.00+75.68%
7/8/2022Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$25.00 ➝ $22.00+45.12%
3/8/2022Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetHold$31.00 ➝ $29.00+109.99%
3/3/2022Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetSector Perform$22.00 ➝ $16.00+17.99%
11/8/2021BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingHold$22.00+13.34%
11/5/2021Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingHold$19.00-0.47%
8/20/2021The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeNeutral ➝ Sell$17.00 ➝ $10.00-27.75%
8/2/2021Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$74.00 ➝ $67.00+287.73%
5/27/2021JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingHold
5/10/2021Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$33.00 ➝ $20.00+19.98%
5/7/2021Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral$45.00 ➝ $23.00+35.21%
5/6/2021Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetHold$29.00 ➝ $16.00-6.10%
3/1/2021Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$58.00 ➝ $45.00+107.76%
1/15/2021Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeNeutral ➝ Underperform$40.00 ➝ $27.00-7.66%
11/10/2020Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Tiago Fauth
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetHold ➝ Neutral$60.00 ➝ $42.00+12.00%
6/30/2020Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Joel Beatty
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$110.00 ➝ $67.00+47.22%
6/30/2020UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral$135.00 ➝ $57.00+22.06%
6/29/2020Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOverweight ➝ Equal Weight$146.00 ➝ $46.00-40.64%
(Data available from 11/28/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












ICPT Price Target - Frequently Asked Questions

What is Intercept Pharmaceuticals's consensus rating and price target?

According to the issued ratings of 8 analysts in the last year, the consensus rating for Intercept Pharmaceuticals stock is Moderate Buy based on the current 4 hold ratings and 4 buy ratings for ICPT. The average twelve-month price prediction for Intercept Pharmaceuticals is $25.80 with a high price target of $49.00 and a low price target of $14.00. Learn more on ICPT's analyst rating history.

Do Wall Street analysts like Intercept Pharmaceuticals more than its competitors?

Analysts like Intercept Pharmaceuticals less than other Medical companies. The consensus rating for Intercept Pharmaceuticals is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how ICPT compares to other companies.

Do MarketBeat users like Intercept Pharmaceuticals more than its competitors?

MarketBeat users like Intercept Pharmaceuticals more than other Medical companies. 74.79% of MarketBeat users gave Intercept Pharmaceuticals an outperform vote while medical companies recieve an average of 66.12% outperform votes by MarketBeat users.

Does Intercept Pharmaceuticals's stock price have much upside?

According to analysts, Intercept Pharmaceuticals's stock has a predicted upside of 73.76% based on their 12-month price targets.

What analysts cover Intercept Pharmaceuticals?

Intercept Pharmaceuticals has been rated by HC Wainwright, Piper Sandler, Robert W. Baird, and SVB Leerink in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:ICPT) was last updated on 11/28/2022 by MarketBeat.com Staff